Review Article| Volume 50, ISSUE 1, P241-249, March 2023

Anticoagulation Regimens in Pregnancy


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Obstetrics and Gynecology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Heit J.A.
        • Kobbervig C.E.
        • James A.H.
        • et al.
        Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study.
        Ann Intern Med. 2005; 143: 697-706
        • Pomp E.R.
        • Lenselink A.M.
        • Rosendaal F.R.
        • et al.
        Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study.
        J Thromb Haemost. 2008; 6: 632-637
      1. Bulletins—Obstetrics ACoOaGCoP. ACOG Practice Bulletin No. 196: Thromboembolism in Pregnancy.
        Obstet Gynecol. 2018; 132: e1-e17
        • Harter K.
        • Levine M.
        • Henderson S.O.
        Anticoagulation drug therapy: a review.
        West J Emerg Med. 2015; 16: 11-17
        • Kolettis D.
        • Craigo S.
        Thromboprophylaxis in Pregnancy.
        Obstet Gynecol Clin North Am. 2018; 45: 389-402
        • Bates S.M.
        • Greer I.A.
        • Middeldorp S.
        • et al.
        VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
        Chest. 2012; 141: e691S-e736S
        • Cohen H.
        • Arachchillage D.R.
        • Beyer-Westendorf J.
        • et al.
        Direct Oral Anticoagulants and Women.
        Semin Thromb Hemost. 2016; 42: 789-797
        • Wiesen M.H.
        • Blaich C.
        • Müller C.
        • et al.
        The Direct Factor Xa Inhibitor Rivaroxaban Passes Into Human Breast Milk.
        Chest. 2016; 150: e1-e4
        • Bremme K.A.
        Haemostatic changes in pregnancy.
        Best Pract Res Clin Haematol. 2003; 16: 153-168
        • Casele H.L.
        • Laifer S.A.
        • Woelkers D.A.
        • et al.
        Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy.
        Am J Obstet Gynecol. 1999; 181: 1113-1117
        • Iorio A.
        • Agnelli G.
        Pharmacokinetic optimisation of the treatment of deep vein thrombosis.
        Clin Pharmacokinet. 1997; 32: 145-172
        • Boban A.
        • Paulus S.
        • Lambert C.
        • et al.
        The value and impact of anti-Xa activity monitoring for prophylactic dose adjustment of low-molecular-weight heparin during pregnancy: a retrospective study.
        Blood Coagul Fibrinolysis. 2017; 28: 199-204
        • Nutescu E.A.
        • Spinler S.A.
        • Wittkowsky A.
        • et al.
        Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
        Ann Pharmacother. 2009; 43: 1064-1083
        • Crowther M.A.
        • Spitzer K.
        • Julian J.
        • et al.
        Pharmacokinetic profile of a low-molecular weight heparin (reviparin) in pregnant patients. A prospective cohort study.
        Thromb Res. 2000; 98: 133-138
        • Kjaergaard A.B.
        • Fuglsang J.
        • Hvas A.M.
        Anti-Xa monitoring of low-molecular-weight heparin during pregnancy: a systematic review.
        Semin Thromb Hemost. 2021; 47: 824-842
        • Berresheim M.
        • Wilkie J.
        • Nerenberg K.A.
        • et al.
        A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?.
        Thromb Res. 2014; 134: 1234-1240
        • Horlocker T.T.
        • Wedel D.J.
        • Rowlingson J.C.
        • et al.
        Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition).
        Reg Anesth Pain Med. 2010; 35: 64-101
        • Leffert L.
        • Butwick A.
        • Carvalho B.
        • et al.
        The society for obstetric anesthesia and perinatology consensus statement on the anesthetic management of pregnant and postpartum women receiving thromboprophylaxis or higher dose anticoagulants.
        Anesth Analg. 2018; 126: 928-944
        • Frontera J.A.
        • Lewin J.J.
        • Rabinstein A.A.
        • et al.
        Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.
        Neurocrit Care. 2016; 24: 6-46
        • Simpson E.L.
        • Lawrenson R.A.
        • Nightingale A.L.
        • et al.
        Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database.
        BJOG. 2001; 108: 56-60
        • Kamel H.
        • Navi B.B.
        • Sriram N.
        • et al.
        Risk of a thrombotic event after the 6-week postpartum period.
        N Engl J Med. 2014; 370: 1307-1315
        • Pacheco L.D.
        • Saade G.
        • Metz T.D. SfM-FMSEa. society for maternal-fetal medicine consult series #51: Thromboembolism prophylaxis for cesarean delivery.
        Am J Obstet Gynecol. 2020; 223: B11-B17
        • Richter C.
        • Sitzmann J.
        • Lang P.
        • et al.
        Excretion of low molecular weight heparin in human milk.
        Br J Clin Pharmacol. 2001; 52: 708-710